ClinConnect ClinConnect Logo
Search / Trial NCT06900413

ESP vs. EXORA Blocks for Analgesia in Laparoscopic Cholecystectomy

Launched by AYCAN KURTARANGİL DOĞAN · Mar 27, 2025

Trial Information

Current as of April 30, 2025

Not yet recruiting

Keywords

Erector Spinae Plane Block Exora Block Laparoscopic Cholecystectomy Patient Controlled Analgesia Plane Block

ClinConnect Summary

This clinical trial is comparing two methods of pain relief for patients undergoing a laparoscopic cholecystectomy, which is a minimally invasive surgery to remove the gallbladder. The two methods being tested are called the Erector Spinae Plane (ESP) block and the External Oblique and Rectus Abdominis Plane (EXORA) block. The goal is to see which method helps control pain better after surgery and reduces the need for additional pain medications. Researchers believe that the EXORA block may provide better pain relief than the ESP block.

To participate in this study, individuals must be between 18 and 65 years old and scheduled for an elective laparoscopic cholecystectomy. They should be in good health according to specific criteria, meaning they should have no severe medical issues that could complicate the study. Participants will be randomly assigned to one of the two pain relief methods, and neither the patients nor the doctors will know which method they are receiving to ensure fairness in the results. Overall, participants can expect to help researchers understand which pain relief method is more effective, potentially improving comfort and recovery for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age between 18 and 65 years
  • Undergoing elective laparoscopic cholecystectomy
  • Classified as American Society of Anesthesiologists (ASA) physical status I to III
  • Providing written informed consent
  • Exclusion Criteria:
  • Known allergy or hypersensitivity to local anesthetics
  • Infection or skin lesions at the site of block application
  • Emergency surgical procedures
  • Refusal to participate in the study
  • Uncontrolled arterial hypertension
  • Uncontrolled diabetes mellitus
  • Mental retardation
  • Current use of antidepressant medications
  • Presence of metabolic disorders
  • Known bleeding diathesis
  • Morbid obesity (Body Mass Index \> 40 kg/m²)

About Aycan Kurtarangi̇l Doğan

Aycan Kurtarangi̇l Doğan is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials. Aycan Kurtarangi̇l Doğan prioritizes ethical standards and regulatory compliance, ensuring that all studies contribute meaningful insights to the scientific community. Through a patient-centered approach, the sponsor aims to accelerate the development of effective therapies and improve healthcare solutions across various therapeutic areas.

Locations

Patients applied

0 patients applied

Trial Officials

Aycan KURTARANGİL DOĞAN

Principal Investigator

Kütahya City Hospital

Ali Kaynak

Principal Investigator

Kütahya City Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported